Recently, the quarterly inspection results of Hang Seng index were officially released. The latest results show that Yongtai bio-b (06978) has been included in the Hang Seng Composite Index. This fully shows that the capital market recognizes Yongtai biological's R & D strength, development strategy, investment value and future prospects. The change will take effect from March 7, 2022.
Zhitong finance app learned that the Hang Seng Composite index is compiled by Hang Seng Index Co., Ltd., a wholly-owned subsidiary of Hang Seng Bank of Hong Kong, and is regarded as the main indicator of the performance of the Hong Kong stock market. The index covers the highest 95% of the total market value of securities listed on the main board of the Hong Kong stock exchange, and provides investors with a comprehensive Hong Kong market index. After this change, the number of constituent shares is 517.
It is worth mentioning that it is not easy to enter the Hang Seng Composite Index. In the selection process of constituent stocks, the selection process of Hang Seng Index and composite index is usually rigorous.
According to the detailed rules for the compilation of Hang Seng Composite Index, listed companies must belong to the specified stock candidate pool (University) and meet the market value requirement and velocity requirement before they can be included in the index.
Among them, in terms of stock candidate pool, stocks are usually "one share, one power" ordinary companies (including companies with different rights of the same share and secondary listing companies), real estate trust funds, joint-stock securities and other objects that are first listed on the main board of the Hong Kong Stock Exchange and whose main business area is greater China; In terms of market value requirements, the average circulating market value of all securities in the past 12 months or at the end of the month since listing shall be arranged in descending order, and the ranking of a single subject shall be in the top 95% of the cumulative market value; In terms of liquidity requirements, for companies listed for less than 12 months and transferred from the gem to the main board for less than 12 months, if the trading time is less than 6 months, the monthly turnover rate shall not be less than 0.05%.
It is precisely because of the strict selection conditions of constituent stocks that the Hang Seng Composite Index, as one of the important indexes of the Hong Kong stock market, has always been used as the benchmark for the issuance of index funds, mutual funds and performance measurement.
This time, Yongtai biology was selected into the list of constituent stocks of Hang Seng Composite Index, which fully reflects that the company has reached the market leading level in terms of market value and liquidity since it was listed in Hong Kong. Being selected will also help to further enhance the company's popularity in the international capital market.
In fact, the key reason why Yongtai biology can be widely recognized by the market and investors is that the company devotes itself to R & D and actively promotes the commercialization of core products, so as to realize the continuous growth of internal value.
In recent years, Yongtai biology has maintained a relatively leading state in the research and development of EAL (amplified activated lymphocytes) solid tumor liver cancer and car-t hematoma leukemia in China.
At present, there are no similar products in the market of the same kind of biological products in Yongtai, so it will not lead the market for at least 5 years. In terms of commercialization, compared with other cellular immunotherapies, eal has a wide range of effects and less side effects, and has a proprietary cell culture method, which can realize large-scale, standardized and automatic production. Therefore, eal may be able to fully enjoy this first mover advantage in the market and effectively increase the profits for Yongtai biology.
In addition to the core product eal, the phase I clinical trial of the company's car-t series candidate product car-t-19 injection has also made phased progress recently. Moreover, since only two similar products have been approved in China, car-t-19 is at the head of this track. Both phased progress and market competition fully show that Yongtai biology not only maintains an absolute leading momentum in the field of solid tumors, but also has strong competitiveness in the field of hematoma.
In July 2021, Yongtai biology introduced the heavyweight investor China Resources pharmaceutical. It is worth mentioning that at that time, China Resources medicine announced its strategic investment in Yongtai biology at the key node where the 2021 mid-term report of Yongtai biology was not released and the latest progress of core product commercialization was not publicly disclosed, indicating that China Resources medicine may have made detailed adjustments to Yongtai biology and be full of confidence in the commercialization of its upcoming core products, This also reflects that the commercialization potential of Yongtai biology can not be ignored, and the commercialization certainty of core products is very high.
On January 12, 2022, Yongtai biology announced that in order to express confidence in the long-term value of the company, the founders and controlling shareholders of the company made a commitment to prohibit the sale of the company. The additional commitment after the lifting date shows that the senior management of the company is optimistic about the follow-up development of Yongtai biology.
At the same time, many institutions also showed great favor for Yongtai biology. China Industrial Securities Co.Ltd(601377) said that the core product eal of Yongtai biology is in the middle and late stage of research and development and has high technical barriers. The company is taking a series of commercialization actions, which is expected to become a long-term driving force for future performance growth and deserves long-term attention.
